bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

pharmafile | November 27, 2018 | News story | Manufacturing and Production, Research and Development |  Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma 

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage small cell lung cancer (SCLC) without disease progression following the completion of first-line platinum-based chemotherapy.

Compared to placebo, the manufacturer said that its PD-1 inhibitor/CTLA-4 inhibitor combo failed to improve the Phase 3 trial’s primary endpoint of overall survival compared to placebo. It is not known whether the therapy managed to meet its secondary endpoint of overall survival improvement for Opdivo as a monotherapy.

News of the failure send shares falling by 4%. BMS said that it would be working with investigators on the study to ensure the publication of full results from the study.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cizzle Biotechnology expands US rollout of lung cancer blood test

Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …

The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026